
    
      Patients with grade 2-4 hemorrhagic cystitis will be randomized to receive either decidual
      stromal cell therapy at approximately 1x106 cells/kg or placebo on two occasions at weekly
      intervals. Patients not responsive within 2 weeks will receive decidual stromal cells at
      approximately 1x106 cells/kg openly.
    
  